Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Metabolex has dosed the first cohort of healthy subjects in a Phase I clinical trial of MBX-2982, a potential first-in-class treatment for type 2 diabetes.
Subscribe to our email newsletter
The Phase I clinical trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of MBX-2982. Investigators expect to enroll a total of 60 healthy volunteers in the 6-cohort ascending-dose study.
MBX-2982 is an agonist of GPR119, a G-protein coupled receptor that is expressed in pancreatic islets and the gastrointestinal tract. Pre-clinical studies conducted by Metabolex and others show that GPR119 agonists can stimulate glucose-dependent insulin secretion and may preserve beta cell health.
David Karpf, chief medical officer of Metabolex, said: “Advancing MBX-2982 into Phase I represents a significant achievement in the expansion of our clinical pipeline and further validates our research and development capabilities.”